Chiron Corporation (Nasdaq:CHIR) today announced that the staff of the Securities and Exchange Commission (SEC) has decided to terminate its investigation of whether Chiron violated any federal securities laws in connection with the previous suspension by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of Chiron's license to manufacture FLUVIRIN(R) influenza virus vaccine and has ended its inquiry into the company's restatement of financial results for the second and third quarters of 2004. Chiron has been informed that no enforcement action has been recommended against the company in connection with these matters. About Chiron Chiron delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology. The company works to deliver on the limitless promise of science and make a positive difference in people's lives. For more information about Chiron, please visit www.chiron.com.
Grafico Azioni Chiron (NASDAQ:CHIR)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Chiron
Grafico Azioni Chiron (NASDAQ:CHIR)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Chiron